Synthetic Genomics Asset Acquisition (Details) - USD ($)			12 Months Ended
	Dec. 20, 2018	Feb. 28, 2018	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest expense			$ 0	$ 64,000
C3J [Member] | Synthetic Genomics Inc [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid for productive assets		$ 1,000,000.0
Cash paid acquisition of assets			$ 2,000,000.0
Percentage of fully diluted capitalized for issuance of common stock		10.00%
Maximum potential milestone payments		$ 39,500,000
C3J [Member] | Scenario Amended Expected Payment One [Member] | Synthetic Genomics Inc [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets	$ 1,000,000.0
C3J [Member] | Scenario Amended Expected Payment Two [Member] | Synthetic Genomics Inc [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets	1,000,000.0
C3J [Member] | Scenario Amended Expected Payment Three [Member] | Synthetic Genomics Inc [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets	$ 2,000,000.0